Vorinostat

Generic Name
Vorinostat
Brand Names
Zolinza
Drug Type
Small Molecule
Chemical Formula
C14H20N2O3
CAS Number
149647-78-9
Unique Ingredient Identifier
58IFB293JI
Background

Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned using combinations of vorinostat with other drugs.

Indication

用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。

Associated Conditions
Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
Associated Therapies
-
Clinical Trials
Related News

Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)

Phase 2
Completed
Conditions
Soft Tissue Sarcoma
Interventions
Drug: Vorinostat
First Posted Date
2009-06-11
Last Posted Date
2018-10-17
Lead Sponsor
Heidelberg University
Target Recruit Count
40
Registration Number
NCT00918489
Locations
🇩🇪

Comprehensive Cancer Center North, University Hospital Kiel, Kiel, Germany

🇩🇪

Department of Hematology, Oncology, Rheumatology and Immunology, University Hospital Tübingen, Tübingen, Baden-Württemberg, Germany

🇩🇪

Center for Soft Tissue Sarcoma, University Hospital Tübingen, Tübingen, Germany

and more 4 locations

Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

First Posted Date
2009-06-11
Last Posted Date
2020-02-25
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
40
Registration Number
NCT00918723
Locations
🇺🇸

Swedish Cancer Institute-Breast Center at First Hill Campus, Seattle, Washington, United States

🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

First Posted Date
2009-05-29
Last Posted Date
2018-09-10
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
15
Registration Number
NCT00910000
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

Phase 2
Completed
Conditions
Advanced Cancer
Interventions
Drug: vorinostat
First Posted Date
2009-05-25
Last Posted Date
2015-05-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
27
Registration Number
NCT00907738

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

First Posted Date
2009-05-08
Last Posted Date
2019-05-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
52
Registration Number
NCT00895934
Locations
🇺🇸

Stanford University Hospitals and Clinics, Stanford, California, United States

🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

🇺🇸

University of Washington Medical Center, Seattle, Washington, United States

and more 1 locations

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

First Posted Date
2009-04-16
Last Posted Date
2017-12-28
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
15
Registration Number
NCT00882206
Locations
🇺🇸

University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States

Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)

Phase 2
Completed
Conditions
Lymphoma
Interventions
Drug: Vorinostat
First Posted Date
2009-04-03
Last Posted Date
2020-10-29
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
56
Registration Number
NCT00875056

Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System

First Posted Date
2009-03-23
Last Posted Date
2022-01-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
33
Registration Number
NCT00867178
Locations
🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

🇺🇸

Lurie Children's Hospital-Chicago, Chicago, Illinois, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

and more 12 locations

Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Vorinostat
Drug: Bortezomib
First Posted Date
2009-03-09
Last Posted Date
2021-04-09
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
9
Registration Number
NCT00858234

Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients

Phase 1
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: Vorinostat
First Posted Date
2009-03-06
Last Posted Date
2017-09-06
Lead Sponsor
Tiziana Marangon
Target Recruit Count
18
Registration Number
NCT00857324
Locations
🇮🇹

Dipartimento Medicina Clinica e Sperimentale, Padova, Italy

🇮🇹

Policlinico Universitario di Udine, Udine, Italy

🇮🇹

A.O.U. S. Giovanni Battista, Torino, Italy

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy